Výsledky vyhledávání

Impact of Baseline Characteristics on the Efficacy and Safety of Eptinezumab in Patients With Migraine: Subgroup Analyses of PROMISE-1 and PROMISE-2

Autor: Vincent, Martin, A Jim, Nagy, Marina, Janelidze, Gvantsa, Giorgadze, Joe, Hirman, Roger, Cady, Lahar, Mehta, Dawn C, Buse

Publikováno v: Clinical Therapeutics. 44:389-402

In the PROMISE-1 (Prevention of Migraine via Intravenous ALD403 Safety and Efficacy-1) and PROMISE-2 (Prevention of Migraine via Intravenous ALD403 Safety and Efficacy-2) clinical trials, eptinezumab 100 mg and 300 mg met the primary efficacy end poi

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::232bc630370f050b241cb1014802d8b1
https://doi.org/10.1016/j.clinthera.2022.01.006

Zobrazit plný text záznamu

Positive response to galcanezumab following treatment failure to onabotulinumtoxinA in patients with migraine: post hoc analyses of three randomized double‐blind studies

Autor: Sheena K. Aurora, Abraham Jim Nagy, Eric Pearlman, Kory Schuh, Jessica Ailani, Qi Zhang

Publikováno v: European Journal of Neurology

Background and purpose Humanized monoclonal antibody galcanezumab, which binds to calcitonin-gene-related peptide, has shown efficacy for episodic and chronic migraine prevention. These analyses evaluated galcanezumab response for migraine headache p

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::868666be2e4da038f43753fde9355ac5
https://doi.org/10.1111/ene.14102

Zobrazit plný text záznamu

100% Response Rate to Galcanezumab in Patients With Episodic Migraine: A Post Hoc Analysis of the Results From Phase 3, Randomized, Double-Blind, Placebo-Controlled EVOLVE-1 and EVOLVE-2 Studies

Autor: Dustin D. Ruff, Abraham Jim Nagy, Eric M. Pearlman, Noah Rosen, Kathleen Day

Publikováno v: Headache

Objective To characterize adult patients with episodic migraine who achieved 100% response to galcanezumab treatment. Background Galcanezumab is a humanized monoclonal antibody that selectively binds to the calcitonin gene‐related peptide (CGRP) an

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9c4a0af7384a8c6f3bfdcd569c811bcf
https://doi.org/10.1111/head.13427

Zobrazit plný text záznamu